|
Böttcher-Bühler, E., & Szostecki, C. (2002). Sonderbericht Chronische Hepatitis C : Pegyliertes Interferon U-2a : Lebensqualitat steigt bei erfolgreicher Therapie deutlich an. MMW : Fortschritte der Medizin, 144(48), 52–53.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Dalgard, O., Bjøro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., et al. (2002). Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years' Follow-Up. European addiction research, 8, 45–49.
Abstract: Aim of the Study: To assess the long-term hepatitis C (HCV) treatment outcome in former injecting drug users (IDUs). Materials and Methods: A long-term follow-up of 27 former IDUs who had been successfully treated for chronic hepatitis C was performed. These patients represented ailiDUs who had obtained a sustained virological response in a Norwegian HCV treatment trial. The patients had been treated with interferon-a alone or in combinatlon with ribavirin. At 5 years’ follow-up the 27 IDUs were retested for HCV RNA and risk behaviour for HCV transmission after treatment was assessed. In the control group ail 18 non-IDUs who had obtained a sustained virological response in the same treatment trial were included. Results: At follow-up 13-82 months (median 64) after the end of treatment only one case of probable reinfection was seen among the 27 IUDs. No reoccur- rence of HCV was observed in the control group. The IDU who was HCV RNA positive at follow-up had continued injecting drugs and reported frequent needle sharing. At follow-up HCV of genotype 1a was detected in contrast to genotype 1b before treatment indicating that this patient was reinfected with HCV. A return to injecting drug use occurred in 9 (33%) of 27 IDUs. Conclusion: The long-term outcome of HCV treatment in former IDUs was excellent. Despite frequent reinitiation of drug injection ail but 1 remained HCV RNA negative.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Seller, C. (2001). Treatment Denied : Inmates and Hepatitis C. Harm Reduction Communication, 11, 14–16.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Finch, E., & Griffiths, P. (1996). Questions and Answers – Hepatitis C. Drug News, Summer 96, 18–22.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Kerssemakers, R. (1996). Hepatitis C – A Forgotten Virus. Jellinek Quarterly, 1(03/1996), 2–3.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Rau, T. (1999). Über Risiken der Hepatitis-B-Impfungen : eine Problematik in ganzheitlicher Sicht. SANUM-Post, 48, 22–23.
Keywords: health promotion; viral hepatitis; hepatitis B
|
|
|
Grob, P. J. (1992). Hepatitisserologie : Anwendung und Interpretation. Therapeutische Umschau : TU : Monatsschrift für praktische Medizin = Revue thérapeutique : revue mensuelle de médecine pratique, 49(5), 287–301.
Keywords: health promotion; viral hepatitis
|
|
|
Kessler, R., & Ryser, D. H. (1991). Der Drogenpatient als Notfall. Praxis : schweizerische Rundschau für Medizin, 80(3; 15.01.1991), 31–35.
Keywords: harm reduction; monitoring
|
|
|
Deissler, K. J. (1989). Spritzen Sie ihm Naloxon mitten ins Herz. Medical tribune : internationale Wochenzeitung : Ausgabe für die Schweiz, 22(3; 20.01.1989), 24.
Keywords: harm reduction; naloxone
|
|
|
Sattar, S. A., & Springthorpe, V. S. (1991). Survival and disinfectants inactivation of the human immunodeficiency virus : a critical review. Reviews of infectious diseases : medical microbiology, clinical immunology, epidemiology, 13, 430–437.
|
|